Figure 3.
The HR activity of primary ovarian cancer cells strongly correlates with cell sensitivity to PARPis and clinical response
(A) Distributions of HR activity scores for HRP and HRD groups. The means of the two groups are shown.
(B) The difference in the means of IC50 of olaparib between the HRP and HRD groups. The brown dashed line represents the average IC50 value for the HRD group.
(C) A Spearman correlation test was used to measure the relationship between the HR activity score and PARPi sensitivity of primary ovarian cancer cells. For patients with multiple clinical samples, HR activity has been calculated as their average.
(D) Kaplan-Meier analysis for the progression-free survival in 28 patients with ovarian cancer. The brown line represents patients with HRD tumors, while the green line represents those with HRP tumors. All patients received platinum-based chemotherapy. Statistical analysis of survival benefits was performed by log-rank test. See also Table S1.
(E) Distribution of HR activity scores for primary ovarian cancer cells and BRCA-deficient cancer cell lines.
(F) The Kaplan-Meier analysis and log-rank test evaluated different HRD activity threshold cutoff values in analyzing progression-free survival benefits between the HRD and HRP groups.
Statistical significance is represented as the −log10 transformation of the p value in the log-rank test. Each data point shown in (A)–(C) is the mean from at least three independent experiments (n = 3, biological replicates); thirteen of them, which represent patients with multiple clinical samples, are the mean from six independent experiments (n = 6 biological replicates). ∗p < 0.05; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. Statistical analysis was performed by unpaired two-tailed Student’s t test in (A) and Mann-Whitney U test in (B).
See also Figure S3.